Radiance Therapeutics, Inc. (RadianceTx®), an innovation leader in ophthalmic devices, today announced that Dr. Laurence Marsteller, Chief Executive Officer, will present the company at the Glaucoma Research Foundation headline event, Glaucoma 360 New Horizons 2023, that will take place on February 3rd, 2023 in San Francisco, USA.
The Radiance Therapeutics presentation is part of the “Emerging Glaucoma Devices” session to be moderated by Dr. Sahar Bedrood and Dr. Tom Samuelson.
Glaucoma 360 is a series of three days of annual events uniting research, industry, and philanthropy to prevent vision loss from glaucoma. Headlining this event will be the New Horizons Forum which serves as an annual catalyst meeting to bring together the essential stakeholders required to speed the translation of new ideas into clinical practice. The forum will feature presentations, panels, and discussions from CEOs of start-up companies, industry executives, ophthalmic leaders, and venture capitalists, with this year’s theme focusing on speeding the development of new therapies and diagnostics for glaucoma patients.
Dr. Marsteller will also showcase RadianceTx® future development plans for its device, which received a FDA 510(k) clearance on January 11, 2023, at the LSI USA ’23 Emerging Medtech Summit to be held at the Monarch Beach Resort, Dana Point, CA from March 20-23 2023. LSI USA is a unique conference that over 3 days brings together the most innovative emerging medtech players, accredited investors and strategics looking for partnership and investment opportunities.
About RadianceTx®
RadianceTx® is a trademark of Radiance Therapeutics, Inc., a Delaware corporation. For more information visit www.radiancetherapeutics.com
For additional information about Glaucoma 360 New Horizons 2023, please visit: https://glaucoma.org/events/glaucoma-360
For additional information about LSI USA ’23 Emerging Medtech Summit, please visit: https://www.lifesciencemarketresearch.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20230131005970/en/
Contacts
For additional information about Radiance Therapeutics and its technology:
Radiance Therapeutics CEO, Laurence Marsteller: L.Marsteller@radiancetx.com
Business Development, Mark Mayhew: Mark@emmetropes.com
Thomas Masterson, Managing Director, Allele Capital Partners: tmasterson@allelecapital.com
Giorgio Pirazzini, GP Communications: giorgio@gpcommunications.eu
Source: Radiance Therapeutics, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20230131005970/en
